Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice

Journal of Surgical Oncology

Volumn 68, Issue 2, 1998, Pages 79-91

  DeMatos, Pierre ^a   Abdel Wahab, Zeinab ^a   Vervaert, Carol ^a   Hester, Dina ^a   Seigler, Hilliard ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B16 melanoma; Cross reactivity; Dendritic cells; MCA 106 fibrosarcoma; Tumor lysates; Vaccine

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEMBRANE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL LYSATE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; FIBROBLAST; FIBROSARCOMA; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BONE MARROW CELLS; CANCER VACCINES; CROSS REACTIONS; DENDRITIC CELLS; FEMALE; FIBROSARCOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNITY, CELLULAR; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VACCINATION;

EID: 0031839664     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199806)68:2<79::AID-JSO3>3.0.CO;2-H     Document Type: Article

References (86)

1. Egner W, Andreesen R, Hart D: Allostimulatory cells in fresh human blood. Transplantation 1993;56:945-950.
2. Nestle F, Zheng X, Thompson C, et al.: Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinct subsets. J Immunother 1993;151: 6535-6545.
3. Reid CD, Fryer PR, Clifford C, et al.: Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 1990;76:1139-1149.
4. Steinman RM, Witmer MD: Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 1978;75:5132-5136.
5. + T lymphocytes to peptide antigen in vivo. J Immunol 1993;151:6742-6750.
6. + progenitors can prime naïve CD4+ T cells and process soluble antigen. J Immunol 1995;155:5427-5435.
7. + T cells. J Immunol 1995;154:4915-4923.
8. Inaba K, Metlay JP, Crowley MT, Steinman RM: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990;172:631-640.
9. Huang AYC, Golumbek P, Ahmadzadeh M, et al.: The role of bone marrow-derived cells in presenting class I-restricted tumor antigens. Science 1994;264:961-965.
10. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T-lymphocytes. J Exp Med 1995;182:255-260.
11. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
12. Aebersold P, Hyatt C, Johnson S, et al.: Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: Association with clinical response. J Natl Cancer Inst 1991;83:932-937.
13. Teunissen MB, Wormmeester J, Krieg SR, et al.: Human epidermal Langerhans cells undergo profound morphologic and phenotypic changes during in vitro culture. J Invest Dermatol 1990;94: 166-173.
14. Simon JC, Cruz PD, Tigelaar RE, et al.: Adhesion molecules CD11a, CD18, and ICAM-1 on human epidermal Langerhans cells serve a functional role in the activation of alloreactive T-cells. J Invest Dermatol 1991;96:148-151.
15. Larsen CP, Ritchie SC, Pearson TC, et al.: Functional expression of the costimulatory molecule. B7/BB1, on murine dendritic cell population. J Exp Med 1992;176:1215-1220.
16. Flamand V, Sornasse T, Thielemans K, et al.: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-610.
17. Inaba K, Inaba M, Witmer-Pack M, et al.: Expression of B7 costimulator molecules on mouse dendritic cells. Adv Exp Med Biol 1995;378:65-70.
18. Ohshima Y, Delespesse G: T cell-derived IL-4 and dendritic cell-derived IL-12 regulate the lymphokine-producing phenotype of alloantigen-primed naïve human CD4 T cells. J Immunol 1997; 158:629-636.
19. Heufler C, Koch F, Stanzl U, et al.: Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon gamma production by T helper 1 cells. Eur J Immunol 1996;26:659-668.
20. Koch F, Stanzl U, Jennewein P, et al.: High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:741-746.
21. Cella M, Scheidegger D, Palmer-Lehman K, et al.: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752.
22. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-322.
23. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996; 156:2918-2926.
24. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997;15:94-103.
25. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995;1:1297-1302.
26. Celluzzi CM, Mayordomo JI, Storkus WJ, et al.: Peptide-pulsed dendritic cells induce antigen-specific. CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
27. Shimizu J, Suda T, Yoshioka T, et al.: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J Immunol 1989;142:1053-1059.
28. Grabbe S, Bruvers S, Gallo RL, et al.: Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-3661.
29. Boczkowski D, Nair S, Snyder D, et al.: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
30. Grabbe S, Beissert S, Schwarz T, Granstein RD: Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-121.
31. Steinman RM: Dendritic cells and immune-based therapies. Exp Hematol 1996;24:859-862.
32. Inaba K, Inaba M, Romani N, et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-1702.
33. Szabolcs P, Avigan D, Gezelter S, et al.: Dendritic cells and macrophages can mature independently from a human bone marrow-derived post-colony-forming unit intermediate. Blood 1996;87: 4520-4530.
34. Bender A, Sapp M, Schuler G, et al.: Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996;196:121-135.
35. Romani N, Gruner S, Brang D, et al.: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
36. Caux C, Dezutter-Dambuyant C, Schmitt D, et al.: GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-261.
37. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-58.
38. Van den Eynde B, Lethe B, Van Pel A, et al.: The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991;173: 1373-1384.
39. Lethe B, van den Eynde B, van Pel A, et al: Mouse tumor rejection antigens P815 A and P815B: Two epitopes carried by a single peptide. Eur J Immunol 1992:22:2283-2288.
40. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91: 9461-9465.
41. Cox AL, Skipper J, Chen Y, et al.: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
42. Kawakami Y, Eliyahu S, Jennings C, et al.: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
43. Coulie PG, Brichard V, Van Pel A, et al.: A new gene encoding for a differentiation antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
44. Wang RF, Robbins PF, Kawakami Y, et al.: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [erratum published in J Exp Med 1995;181:1261]. J Exp Med 1995;181:799-804.
45. Traversari C, van der Bruggen P, Luescher IF, et al.: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
46. van der Bruggen P, Szikora JP, Boel P, et al.: Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601. Eur J Immunol 1994;24:2134-2140.
47. Boel P, Wildmann C, Sensi ML, et al.: BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175.
48. Van den Eynde B, Peeters O, De Backer O, et al.: A new family of genes encoding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182: 689-698.
49. Van den Eynde B, Gaugler B, van der Bruggen P, et al.: Human tumour antigens recognized by T cells: Perspective for new cancer vaccines. Biochem Soc Trans 1995;23:681-686.
50. + tumor infiltrating lymphocytes. J Immunol 1994;153:1202-1215.
51. DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF: Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998 (in press).
52. Abdel-Wahab ZA, Osanto S, Darrow TL, et al.: Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther 1994;1:171-179.
53. Abdel-Wahab Z, Dar M, Osanto S, et al.: Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Ther 1997;4:33-41.
54. van Rensburg EJ, van Heerden WF, Raubenheimer EJ: Langerhans cells and human papillomaviruses in oesophageal and laryngeal carcinomas. In Vivo 1993;7:229-232.
55. Gallo O, Bianchi S, Giannini A, et al.: Correlations between histopathological and biological findings in nasopharyngeal carcinomas and its prognostic significance. Laryngoscope 1991;101:487-493.
56. Furihata M, Ohtsuki Y, Ido E, et al.: HLA-DR antigen-and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma - their distribution in relation to prognosis. Virchows Arch B Cell Pathol 1992;61:409-414.
57. Tsujitani S, Kakeji Y, Watanabe A, et al.: Infiltration of S-100 protein positive dendritic cells and peritoneal recurrence in gastric cancer. Int Surg 1992;77:238-241.
58. Tsujitani S, Kakeji Y, Maehara Y, et al.: Dendritic cells prevent lymph node metastases in patients with gastric cancer. In Vivo 1993;7;233-237.
59. Zeid NA, Muller HK: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993;25:338-343.
60. Bigotti G, Coli A, Castagnola D: Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate 1991;19:73-87.
61. Nakano T, Oka K, Sugita T, Tsunemoto H: Antitumor activity of Langerhans cells in radiation therapy for cervical cancer and its modulation with SPG administration. In Vivo 1993;7:257-263.
62. Peoples GE, Goedegebuure PS, Smith R, et al.: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92: 432-436.
63. Yoshino I, Goedegebuure PS, Peoples GE, et al.: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-3390.
64. Peoples GE, Smith RC, Linehan DC, et al.: Shared T cell epitopes in epithelial tumors. Cell Immunol 1995;164:279-286.
65. Shamamian P, Kawakami Y, Restifo N, et al.: Recognition of neuroectodermal (NE) tumors by melanoma specific T-cells: Evidence for shared tumor associated antigens (Ag). Proc Am Assoc Cancer Res 1993;34:482.
66. Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 1978;28:149-250.
67. Nanni P, Colombo MP, De Giovanni C, et al.: Impaired H-2 expression in B16 melanoma variants. J Immunogenet 1983;10: 361-370.
68. Celik C, Lewis DA, Goldrosen MH: Demonstration of immunogenicity with the poorly immunogenic B16 melanoma. Cancer Res 1983;43:3507-3510.
69. Cohen EP, Kim TS: Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin Cancer Biol 1994;5:419-428.
70. Bellone M, Iezzi G, Manfredi AA, et al.: In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 1994;24: 2691-2698.
71. Bellone M, Iezzi G, Martin-Fontecha A, et al.: Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J Immunol 1997;158:783-789.
72. Tanaka K, Gorelik E, Watanabe M, et al.: Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol 1988;8:1857-1861.
73. Wells AD, Rai SK, Salvato MS, et al.: Restoration of MHC class I surface expression and endogenous antigen expression by a molecular chaperone. Scand J Immunol 1997;45:605-612.
74. Bloom MB, Perry-Lalley D, Robbins PF, et al.: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-495.
75. Restifo NP, Esquivel F, Kawakami Y, et al.: Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177:265-277.
76. Kaklamanis L, Leek R, Koukourakis M, et al.: Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 1995;55:5191-5194.
77. Weber JS, Jay G, Tanaka K, Rosenberg SA: Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med 1987;166:1716-1733.
78. Chang AE, Shu SY, Chou T, et al.: Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res 1986;46:3426-3430.
79. Shu SY, Rosenberg SA: Adoptive immunotherapy of newly-induced murine sarcomas. Cancer Res 1985;45:1657-1662.
80. Spiess PJ, Yang JC, Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987;79:1067-1075.
81. Chou TA, Chang AE, Shu SY: Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J Immunol 1988;140:2453-2461.
82. Dar MM, Abdel-Wahab Z, Vervaert CE, et al: Immunologic memory induced by genetically transduced tumor cells. Ann Surg Oncol 1996;3:247-254.
83. Abdel-Wahab Z, Dar MM, Hester D, et al.: Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-γ gene modified melanoma cells. Cell Immunol 1996;171:246-254.
84. Anichini A, Mortarini R, Maccalli C, et al.: Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma. J Immunol 1996;156:208-217.
85. Nair SK, Boczkowski D, Snyder D Gilboa E: Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 1997;27:589-597.
86. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998;4:321-327.